Hexaminolevulinate hydrochloride is under clinical development by Asieris Pharmaceuticals and currently in Phase III for Cervical Intraepithelial Neoplasia (CIN). According to GlobalData, Phase III drugs for Cervical Intraepithelial Neoplasia (CIN) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Hexaminolevulinate hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Hexaminolevulinate hydrochloride overview

Cevira (APL-1702) is under development for the treatment of cervical high grade squamous intraepithelial lesion (HSIL) caused by infection with all HPV subtypes. It is hexaminolevulinate (HAL) photodynamic therapy (PDT).

Asieris Pharmaceuticals overview

Asieris Pharmaceuticals discovers and develops drugs for the treatment of genitourinary tumors. The company is investigating APL-1202, an oral drug to treat non-muscle-invasive bladder cancer (NMIBC); APL-1702(Cevira), a photodynamic therapy against cervical high grade squamous intraepithelial lesion (HSIL); and APL-1706 (Hexvix), a fluorescent imaging agent to assist in the diagnosis of bladder cancer. It is also evaluating drugs for triple negative breast cancer, metastatic castration resistant prostate cancer, ER positive breast cancer and other reproductive diseases; autoimmune diseases; and Acinetobacter baumannii infection. Asieris Pharmaceuticals conducts research and development in the therapeutic areas of bladder cancer, oncology, multidrug-resistance infections and tumor immunotherapy. The company operates with additional offices in the US and China. Asieris Pharmaceuticals is headquartered in Pudong, China.

For a complete picture of Hexaminolevulinate hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.